JP2024506228A - 脂質関連障害の処置のための組成物および方法 - Google Patents
脂質関連障害の処置のための組成物および方法 Download PDFInfo
- Publication number
- JP2024506228A JP2024506228A JP2023517276A JP2023517276A JP2024506228A JP 2024506228 A JP2024506228 A JP 2024506228A JP 2023517276 A JP2023517276 A JP 2023517276A JP 2023517276 A JP2023517276 A JP 2023517276A JP 2024506228 A JP2024506228 A JP 2024506228A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- formula
- compound
- pharmaceutical composition
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079195P | 2020-09-16 | 2020-09-16 | |
| PCT/IB2021/000640 WO2022058795A1 (en) | 2020-09-16 | 2021-09-15 | Compositions and methods for the treatment of lipid-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506228A true JP2024506228A (ja) | 2024-02-13 |
| JP2024506228A5 JP2024506228A5 (cg-RX-API-DMAC7.html) | 2024-09-25 |
Family
ID=80776673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517276A Pending JP2024506228A (ja) | 2020-09-16 | 2021-09-15 | 脂質関連障害の処置のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230355584A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4213835A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024506228A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116685316A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021344871A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301325A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022058795A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203468A1 (en) | 2015-06-15 | 2016-12-22 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014533264A (ja) * | 2011-11-15 | 2014-12-11 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | 三環式化合物、それらを含む組成物およびそれらの使用 |
| WO2016020919A1 (en) * | 2014-08-07 | 2016-02-11 | Raziel Therapeutics Ltd. | Compositions comprising tricyclic compounds, and uses thereof |
-
2021
- 2021-09-15 EP EP21868804.2A patent/EP4213835A4/en active Pending
- 2021-09-15 IL IL301325A patent/IL301325A/en unknown
- 2021-09-15 WO PCT/IB2021/000640 patent/WO2022058795A1/en not_active Ceased
- 2021-09-15 US US18/245,132 patent/US20230355584A1/en active Pending
- 2021-09-15 JP JP2023517276A patent/JP2024506228A/ja active Pending
- 2021-09-15 CN CN202180077281.9A patent/CN116685316A/zh active Pending
- 2021-09-15 AU AU2021344871A patent/AU2021344871A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014533264A (ja) * | 2011-11-15 | 2014-12-11 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | 三環式化合物、それらを含む組成物およびそれらの使用 |
| WO2016020919A1 (en) * | 2014-08-07 | 2016-02-11 | Raziel Therapeutics Ltd. | Compositions comprising tricyclic compounds, and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| ABHAY TALATHI ET AL.: "Fat busters: Lipolysis for face and neck", JOURNAL OF CUTANEOUS AND AESTHETIC SURGERY, vol. 11, no. 2, JPN6025045793, 2018, pages 67, ISSN: 0005726648 * |
| SHAMBAN, AVA T.: "Noninvasive Submental Fat Compartment Treatment", PLASTIC AND RECONSTRUCTIVE SURGERY GLOBAL OPEN, vol. Vol.4, Issue 12S, JPN6026032813, December 2016 (2016-12-01), pages 1155 - 1, ISSN: 0005925466 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021344871A9 (en) | 2024-08-08 |
| CN116685316A (zh) | 2023-09-01 |
| AU2021344871A1 (en) | 2023-05-25 |
| WO2022058795A1 (en) | 2022-03-24 |
| US20230355584A1 (en) | 2023-11-09 |
| IL301325A (en) | 2023-05-01 |
| EP4213835A1 (en) | 2023-07-26 |
| EP4213835A4 (en) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7850665B2 (ja) | 血管脂肪腫の処置のための組成物 | |
| WO2001078704A2 (en) | Gaba substrate and the use thereof for treating cognitive and emotional disorders | |
| JP7822308B2 (ja) | 固形腫瘍の処置のための組成物 | |
| KR20140099492A (ko) | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 | |
| AU2020383537A1 (en) | Combination of a BTK inhibitor and an MDM2 inhibitor for cancer treatment | |
| IE922181A1 (en) | The use of sulphur-containing carboxylic acids to combat¹physiologically-induced excitatory disorders and diseases¹related thereto as well as allergic diseases and also the¹preparation of corresponding medicaments | |
| KR20170141774A (ko) | 항바이러스 및 항염증 치료제의 치료 조합물 | |
| US20230355584A1 (en) | Compositions and methods for the treatment of lipid-related disorders | |
| CA2920073A1 (en) | Boosting the effect of methotrexate through the combined use with lipophilic statins | |
| CN109562097B (zh) | 穿心莲内酯治疗多发性硬化的进行形式 | |
| WO2022058792A1 (en) | Compositions for the treatment of fat related conditions and disorders | |
| US20240335424A1 (en) | Compositions and methods for treating lipoma pain | |
| RU2358723C1 (ru) | Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения | |
| HK40077772A (en) | Compositions for the treatment of solid tumors | |
| RU2404976C1 (ru) | Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения | |
| US20200289593A1 (en) | Spirulina carotenoid complex | |
| RU2719376C1 (ru) | Лекарственное средство седативного и миорелаксантного действия | |
| WO2023220768A1 (en) | Acne control formulations | |
| WO2012058993A1 (zh) | 安倍生坦预防或减轻缺氧导致的心功能损伤的用途 | |
| UA68126A (en) | Method for correcting homeostasis upon radiation exposure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240913 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260409 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260805 |